Results 21 to 30 of about 83,328 (323)

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports [PDF]

, 2014
Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen4 (CTLA-4), an inhibitory molecule typically expressed on T cells. Blockade of CTLA-4 induces an overall activation of T cells, including an immune-mediated anti-tumour ...
Brochez, Lieve, Cocquyt, Veronique, KRUSE, VIBEKE, Marlier, Joke, Van Belle, Simon   +4 more
core   +2 more sources

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2019
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, D. Hogg, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, L. Bastholt, J. Rizzo, Á. Balogh, A. Moshyk, F. Hodi, J. Wolchok   +30 more
semanticscholar   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Health and Quality of Life Outcomes, 2012
Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients.
Revicki Dennis A, van den Eertwegh Alfons JM, Lorigan Paul, Lebbe Celeste, Linette Gerald, Ottensmeier Christian H, Safikhani Shima, Messina Marianne, Hoos Axel, Wagner Samuel, Kotapati Srividya   +10 more
doaj   +1 more source

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

PLoS ONE, 2023
ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source

Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma

Case Reports in Endocrinology, 2016
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves’ disease, however, has been rarely reported with this medication.
Umal Azmat, David Liebner, Amy Joehlin-Price, Amit Agrawal, Fadi Nabhan   +4 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

Frontiers in Pharmacology, 2021
Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources.
Xuezhi Hao, Aizong Shen, Bin Wu
doaj   +1 more source

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors [PDF]

, 2019
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium ...
Au, L, Chauhan, D, Edmonds, K, Gore, M, Hughes, P, Husson, O, Lai, Z, Larkin, J, Lingard, K, Ludlow, A, Lynch, J, Mann, J, Mclean, E, O'Reilly, A, Pattison, N, Teh, JJ, Turajlic, S, Wiseman, T   +17 more
core   +3 more sources

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2022
BACKGROUND Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit.
M. Rohaan, T. H. Borch, J. H. van den Berg, Ö. Met, R. Kessels, M. G. Geukes Foppen, J. Stoltenborg Granhøj, B. Nuijen, C. Nijenhuis, I. Jedema, M. van Zon, Saskia Scheij, J. Beijnen, Marten Hansen, C. Voermans, I. M. Noringriis, T. Monberg, R. Holmstroem, L. Wever, M. V. VAN DIJK, L. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, M. Karger, J. Borgers, Renske M T ten Ham, V. Retèl, W. V. van Harten, F. Lalezari, H. van Tinteren, A. V. D. van der Veldt, G. Hospers, Marion A. Stevense-den Boer, K. Suijkerbuijk, M. Aarts, D. Piersma, A. van den Eertwegh, J. D. de Groot, G. Vreugdenhil, E. Kapiteijn, M. Boers-Sonderen, W. Fiets, F. van den Berkmortel, E. Ellebaek, L. Hölmich, A. V. Van Akkooi, W. V. van Houdt, M. Wouters, J. V. van Thienen, C. Blank, A. Meerveld-Eggink, S. Klobuch, S. Wilgenhof, T. Schumacher, M. Donia, I. Svane, J. Haanen   +56 more
semanticscholar   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources